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Contrary to the scepticism that characterised the planning stages of the human genome project, the 
technology and sequence data resulting from the project are set to revolutionise medical practice for 
good. The expected benefits include:  enhanced discovery of disease genes, which will lead to 
improved knowledge on the genetic basis of diseases; availability of DNA-based diagnostic methods, 
which will find widespread application in preimplantation diagnosis, carrier screening, presymptomatic 
testing and population screening; the availability of more effective and more tolerant drugs, which will 
result in more effective therapies characterised by higher potency and reduced incidence of adverse 
reactions. However, there are still a number of technological, ethical, legal and social obstacles that 
must be addressed before these medical advances are incorporated into routine clinical practice.  To 
justify the huge investments in the human genome project, the new advancements should be affordable 
by all, and must not result in a further widening of the gap between the quality of healthcare available in 
the resource-rich and the resource-poor countries. 
. 





The 20th century was characterised by remarkable 
improvements in the understanding of the aetiology of 
diseases, which led to significant advancements in the 
fields of disease prevention, diagnosis and therapy 
(Table 1). Although these developments brought about a 
significant increase in the average life expectancy of 
human populations all over the world, the much-desired 
health for all by the year 2000 seemed a fleeting illusion 
as the twilight of the 20th century approached.  
This was mostly because a number of diseases arising 
from different types of inherited and acquired genetic 
defects continued to plague a significant proportion of the 
human population. The best known of these are the 
thousands of monogenic conditions, e.g., cystic fibrosis 
(Donaldson and Boucher, 2003), sickle cell anaemia 
(Weatherall and Provan, 2000) and Huntington’s disease 
(MacDonald et al., 2003) caused by mutations that affect 
a single gene. These diseases have been catalogued in a 
book, ‘Mendelian Inheritance in Man’ (McKusick, 1998) 
and its online version, the Online Mendelian Inheritance 
in Man (OMIM), which can be accessed from the NCBI 
homepage: http://www.ncbi.nlm.nih.gov/omim. The others 
are the polygenic or multifactorial diseases, e.g., 
cardiovascular diseases, cancers, hypertension, 
diabetes, Alzheimer’s disease, Parkinson’s disease, 
arthritis and obesity, caused by mutations affecting more 
than one gene and in which the environment also plays a 
role (Carbonin et al., 2003; Dekker et al., 2003; Florez et 
al., 2003), the chromosomal abnormalities e.g., Down’s 
syndrome, caused by deletions, duplications or 
translocations of sections of the chromosome (Roizen 
and  Patterson,  2003;  Andrieux  et  al.,  2002)   and   the  
 




                                Table 1. Some of the major medical advances of the 20th century. 
 
Therapy Diagnosis  
Discovery of antibiotics 
Development of vaccines 
Discovery of insulin 
Discovery of blood groups  
Invention of the dialysis technique 
Radiotherapy 
Organ transplantation 
Use of anaesthesia  





Magnetic Resonance Imaging (MRI) 
Electroencephalogram (EEG) 
MT Scan 





mitochondrial diseases caused by mutations in the non-
chromosomal DNA contained in the mitochondrion (Graff 
et al., 2002; Schapira, 2002).  
Although there had never been much doubt that the 
information needed to find a cure for these diseases laid 
hidden in the human genome, the scientific community 
lacked the conviction to embark on the ‘adventure’ of 
unravelling the estimated 3 billion base pairs that make 
up the human genome until the last decade of the 20th 
century. The need to identify these ‘errors’ in genes and 
to unravel the mechanisms through which they contribute 
to the different diseases was the overriding justification of 
the human genome project (Human Genome Project 
Information, 2003).  
With the release of the first draft of the human genome 
sequence in June 2000 (HGPI, 2000; Lander et al., 2001; 
Venter et al., 2001), the scepticism that characterised the 
planning and initial phase of the project gave way to 
optimism as the emphasis shifted to ways to optimise the 
benefits of the genome information arising from the 
project (Chakravarti, 2001; Collins and McKusick, 2001; 
Futreal et al., 2001; Jimenez-Sanchez et al., 2001). The 
subsequent publication of the final genome sequence on 
April 14 2003 has attracted worldwide interest on how 
medical practice will change in the post genomic era 
(Burke, 2002; Collins et al., 2003; Guttmacher and 
Collins, 2002; Guttmacher and Collins, 2003; Khoury et 
al., 2003; Weinshilboum, 2003). This paper is a 
contribution to the increasing pile of reviews on how 
medical practice will change as a result of the completion 
of the human genome project.  
 
 
A BRIEF HISTORY OF THE HUMAN GENOME 
PROJECT 
 
The human genome project (HGP) was initiated in 1990 – 
after about 5 years of planning - against a background of 
scepticism (Roberts, 2001, Service, 2001), as a 
multinational project (involving 20 research institutions 
located mostly in China, France, Germany, Great Britain, 
Japan and the United States) to determine the entire 
sequence and develop the genetic and physical maps of 
the entire human genome.   
The Human Genome Project was designed as a 15-
year project (1999 – 2005) with a number of major goals 
in mind (HGPI, 1990; Collins and Gallas, 1993):   
 
1. To unravel the entire human DNA sequence and to 
make the data accessible to the public and scientific 
community;  
2. To develop efficient technology to sequence human 
DNA;  
3. To identify the variations in the genetic code of 
humans that predispose to different diseases, 
particularly the single nucleotide polymorphisms 
(SNPs) that are responsible for interindividual 
differences;  
4. To understand how specific genes and/or groups of 
genes interact exclusively or with some 
environmental factors to determine predisposition of 
individuals to disease or good health;  
5. To also decipher the genetic code of some model 
organisms like yeast (C. cerevisae), roundworm (C. 
elegans) and the fruit fly (D. melanogaster), which is 
expected to facilitate the understanding of gene 
functions in a more complex genome like that of 
humans;  
6. To identify the ethical, legal and social implications of 
genome research and other obstacles that would be 
overcome before the results of the HGP can be 
successfully integrated into medical practice; 
7. To develop Bioinformatics tools and manpower to 
facilitate the gathering, analysis and subsequent 
storage of the increasing amounts of sequence data 
that will arise from the project (National Human 
Genome Research Institute, 2003).  
 
The first draft of the sequence was released in June 
2000, while the final draft was released in April 2003 - 
two years ahead of the projected 2005 date. Other 






of the genomes of the model organisms were also met 
and even exceeded (HGPI, 2003a). The surprising 
revelations of the genome project include 1), the 
discovery that there are only about 30,000 – 35,000 
genes in the human genome, and 2). The realisation that 
any two unrelated people are thought to share about 
99.9% of their genome, and that the remaining 0.1% is 
responsible for all the interindividual variations observed 
in people. Cataloguing these variations known as single 
nucleotide polymorphisms (SNPs) and matching them 
with their respective phenotypes has been identified as 
the next milestone for the human genome project.   
Since the completion of the project, scientists have 
been relatively united in the opinion that human genome 
project will live up to its promise as ‘the single most 
important project undertaken by biomedical scientists. 
There is no doubt that the impact of the genome project 
on biology, biomedical research, biotechnology and 
clinical practice will be unprecedented and durable 
(Collins et al., 2000). Aspects of medical practice being 
revolutionised by the human genome project include 
disease discovery, disease diagnosis and prediction, 
discovery of new drugs and therapies. 
 
 
THE GENETIC BASIS OF DISEASES  
 
Although the genetic basis of diseases has been known 
for millennia, genetic diseases were perceived as rare 
diseases for the most of the 20th century, and the field of 
genetics was studied as a speciality different from 
medicine. Recent advances in medical research have, 
however, continued to reveal that genes interact with the 
environment in yet unknown ways to affect the severity 
and predisposition of individuals to many common health 
conditions, many of which were not thought to have a 
genetic component (Thomson and Esposito, 1999; 
Munnich and Feingold, 2003).  
The number of diseases known to have a genetic 
component has increased significantly in recent years, 
and includes cardiovascular diseases (Aouizerat et al., 
2002), diabetes (Florez et al 2003), stroke (Rosand and 
Altshuler, 2003), cancers (Antoniou and Easton, 2003), 
Alzheimer’s disease (Ezquerra et al., 2003) Parkinson’s 
disease (Dekker et al., 2003) arthritis (Svendsen et al., 
2003; Olofsson and Holmdahl, 2003), hypertension 
(Morris et al., 2003) and obesity (Boutin and Froguel, 
2003). Many of these are ranked amongst the leading 
causes of death, especially in the developed countries 
(Gray, 2000; Guttmacher, 2000).  Similarly, genetic 
variations have been linked with differing susceptibilities 
to many other diseases, including the infectious diseases, 
malaria (Omi et al., 2002; 2003) and HIV/AIDS (Michael, 
1999), which are the major causes of death in developing 
countries of Africa and Asia, and the newly identified new 
Variant Creuzfeldt-jakob disease and related prion 
diseases (Weissman,  1996;  Nwanguma  and  Orisakwe,  




2003). Thus, genetic illnesses are no longer perceived as 
‘rare’ disorders, which arise directly as a result of gene 
mutations and chromosomal aberrations, but include the 
many common diseases in which genetics plays a role in 
determining an individual’s susceptibility or the severity of 
disease suffered by an individual. It is believed in some 
circles that all diseases have a genetic component, and 
that some of the so-called monogenic diseases may 
actually be polygenic because of the contribution of other 
genes in determining the severity of the disease in 
individual cases.  
 
 
DISEASE DISCOVERY AND DIAGNOSES  
 
The fields of disease discovery and diagnostics are two 
of the many areas in which the human genome project 
will bring about a major revolution in the 21st century, 
because the identification and eventual location of all 
human genes will reveal the mechanism and pattern of 
inheritance of all monogenic diseases and the many 
other common diseases in which genetics plays a role in 
increasing an individual’s resistance or vulnerability. 
Significant achievements have already been recorded in 
the area of disease discovery since the commencement 
of the human genome project. For example, the number 
of identified human disease genes has increased from 
less than 100 in 1990, when the human genome project 
started, to over 1,400 in 2003 (Drell and Adamson, 2003). 
These include genes associated with a wide variety of 
diseases including the neurodegenerative diseases - 
Alzheimer’s disease, multiple sclerosis and Parkinson's 
disease (Mathisen, 2003), asthma (Van Eerdewegh, 
2002) dyslexia (Francks et al., 2002) cystic fibrosis, 
diabetes (Walder et al., 2003), Duchenne’s muscular 
dystrophy, myotonic dystrophy, neurofibromatosis, 
retinoblastoma, a variety of cancers (Egland et al., 2002; 
Suzuki et al., 2002), etc. This is because the availability 
of the human genome data and associated technologies - 
including position cloning (Nickel et al., 1997; Collins, 
1992), sequence based gene discovery and retroviral 
tagging (Suzuki et al., 2002) - have made the process of 
gene discovery easier and a lot faster. With these 
technologies, especially positional cloning, it is now 
possible to discover the genetic basis of a disease and 
identify the disease gene without knowing the exact 
function of the gene (Collins, 1999; Olofsson and 
Holmdahl, 2003). 
Further evidence of the rapid rate of progress in the 
field of disease discovery is presented by the rate at 
which the database, Online Mendelian Inheritance in Man 
available at the website http://www.ncbi.nlm.nih.gov/omim 
is updated. With time, it is believed, that the mechanisms 
by which these and several other genes cause diseases 
independently, or in association with a number of critical 
environmental factors (known and unknown) will also be 
uncovered.   Already,   a   new   venture   known   as   the  
 




International ‘HapMap’ project – involving scientists at the 
John Hopkins University and an International Consortium 
of Scientists from six countries - Canada, China, Japan, 
Nigeria, United States of America and The United 
Kingdom – has been initiated since 2002 to facilitate the 
discovery of the genes that contribute to such complex 
diseases as cancer, diabetes, heart disease, etc.  
(NHGRI, 2002)  
One direct clinical impact of the reported progress in 
the discovery of disease genes is the development of 
gene or DNA-based diagnostic tests for the respective 
genetic disorders. Already, DNA-based tests or (gene 
tests), which involve the direct examination of the DNA 
molecule (Jurkovic et al., 1995), are being used to test for 
certain genetic disorders (Table 2). Such DNA-based 
tests are more effective than biochemical methods, which 
are based on the measurement of gene products (like 
enzymes) and cytological methods based on the 
microscopic examination of labelled or stained 
chromosomes (Wolpert, 2000). In DNA – based tests, a 
patient’s DNA, which could be obtained from any tissue, 
is scanned for mutated sequences. For some types of 
gene tests, probes, whose sequences are 
complementary to the mutated sequence, are used to 
detect the presence or absence of a genetic disease. 
Another type of DNA testing involves comparing the 
sequence of DNA bases in a patient’s gene to a normal 
version of the gene. Some clinical applications of gene 
tests are listed in Table 3. 
 
 
Table 2. A list of some of the diseases for which DNA-based gene 




Cystic fibrosis  
Gaucher disease 
Duchenne muscular dystrophy 
Fragile X syndrome 
Huntington’s disease 
Inherited breast cancer 
Inherited ovarian cancer 
Myotonic dystrophy 
Phenylketonuria 






In addition to use in routine diagnoses, the newly 
developed DNA tests will find wide applications in 
prenatal and postimplantation diagnoses, newborn 
screening, carrier testing, presymptomatic testing, or for 





diseases like Huntington’s disease and Alzheimer’s 
disease confirmatory diagnosis of a symptomatic 
individual and in forensic medicine (Williams and Schutte, 
2000; Burke, 2002; Pierce et al., 2003). The list of 
diseases for which gene tests exist has increased 
significantly in recent times, and currently includes 
Alzheimer’s disease, Duchenne muscular dystrophy, 
Huntington’s disease, sickle cell anaemia, Adult 
polycystic kidney disease, phenylketonuria, cystic 
fibrosis, Gaucher’s disease, inherited breast and ovarian 
cancer, thalassamias and haemophilia (Burke, 2002, 
Gene Tests, 2003). An advanced form of gene testing, 
involves the use of the so - called, DNA chips 
(microarrays) to detect the presence in the DNA of an 
individual of a wide variety of genetic defects which 
cause or predispose to a number of diseases (Aitman, 
2001).  In addition to mutation detection, these biochips, 
like they are called, also offer enormous opportunities for 
use in biomedical research in the analysis of protein 
expression, (especially in cancer research) the 
understanding of gene function and gene discovery 
(Clark et al., 2000; Miyaoka et al., 2001. In addition, 
based on the revealed information on the human genome 
and the genome of the model organisms, including those 
of mouse and rat, ideal animal models can be created for 
all human diseases. Such models, which will enhance the 
understanding of gene functions and disease 
mechanisms (through comparative genomics), currently 
exist for a number of diseases, including diabetes, sickle 
cell anaemia and cancer (Fortini and Bonini, 2000). Such 
models will also be useful in animal trials for new drugs 




DRUG DEVELOPMENT AND THERAPY 
 
It is widely believed that drug therapy often fails to 
achieve the desired cure, may not be efficacious in a 
significant proportion of treated patients, and causes 
severe, and, sometimes, life threatening toxicities in 
some patients (Lee, 2003). Adverse drug effects, is 
believed to be responsible for a significant proportion of 
deaths recorded in hospitals  (Lazarou et al 1998., 
Goldstein, 2003.). Although factors like differences in 
age, sex, weight and physiological state, concomitant 
therapy and drug interactions affect drug response in 
individuals, genetic variability amongst individuals has 
been recognised as a major determinant of variable drug 
effect and, therefore, therapy outcome (Pedley and 
Hirano, 2003). The newly emerging field of 
Pharmacogenomics (coined from pharmacology and 
genomic) studies how the entire genetic constitution of an 
individual determines his body’s response to drugs 
(Rioux, 2000). Thus, pharmacogenomics deals with 
genetic variations (polymorphisms) in drug receptors (List 
and Habener, 2003), transporters (Siddiqui et  al.,  2003),  
 




                       Table 3. Clinical applications of gene tests. 
 
Type of test Clinical application 
Carrier screening 
 
Identification of people carrying a single copy of a 
gene that requires two copies for disease 
manifestation. E.g., in sickle cell anaemia.  
Preimplantation genetic diagnosis 
 
Screening embryos for genetic defects before 
implantation during in vitro fertilisation 
Prenatal diagnosis 
               
Testing the foetus for the presence of genetic 
defects. E.g., screening for Down’s syndrome 
and the haemoglobinopathies.  
Newborn screening 
 
Testing of newborns for inborn genetic defects. 
E.g.,phenylketonuria   
Presymptomatic testing 
 
Detection of a predisposing gene in an individual 
before the manifestation of disease symptoms, 
e.g., in the detection of adult onset diseases like 
Alzheimer’s disease and Huntington’s disease. 
Confirmatory diagnosis 
 
The confirmation of the presence of a disease in 
a symptomatic individual. 
Identity testing (Forensics)  Matching organ donors with recipients during 
transplantation, confirmation of paternity and 
family relationships, Identification of accident 




other drug targets and the drug-metabolising enzymes, 
which are responsible for the interindividual variations in 
rates of drug disposition and response (Evans and 
Relling, 1999; Evans and McLeod, 2003). All 30 families 
of drug metabolising enzymes known are believed to 
show such variations capable of resulting in varying drug 
response. Following the completion of the human 
genome project, it would be possible to identify and 
distinguish individuals who can metabolise a drug rapidly 
form those who metabolise it slowly or who do not 
metabolise it at all, and to distinguish those who show an 
adverse reaction to a drug from those who do not (Lewis 
and Manning, 1999; Gray, 2000; Turner and Boerwinkle , 
2001). 
The anticipated benefits of pharmacogenomics will 
revolutionise drug therapy in a number of ways. In due 
course, pharmaceutical companies would be able to 
create more specific, more efficient and less toxic drugs. 
In addition to being able to prescribe the most suitable 
drug for a patient without first trying out a variety, doctors 
would be able to base drug dosages on the patient’s 
genetic ability to metabolise the drug and no longer on 
age and weight as is currently the case. Another direct 
outcome of the human genome project will be in the 
identification of novel drug targets (Chan et al., 2002; 
Williams, 2003) and the eventual development of more 
efficient vaccines, which will be made from DNA or RNA. 
Nucleic acid vaccines combine all the desirable attributes 
of existing vaccines without the associated problems, 
especially the risk of zoonotic infection, which is a major 
problem with current vaccines derived from animal 
tissues. In addition, DNA vaccines will be more stable 
and easier to preserve, especially in the developing 
countries where vaccine preservation is a source of worry 
in public health sectors. DNA vaccines could also be 
engineered to carry multiple strains of a pathogen at 
once.   
Following from these, the process of drug discovery 
and testing will become less demanding, as target 
populations for therapy and clinical testing will be chosen 
more specifically based on their genetic make-up. 
Ultimately, these changes will bring about an eventual 
decrease in the overall cost of health care. 
Pharmacogenomics thus holds the promise that in the 
future drugs can be “tailor-made” or “designed” to match 
the genetic constitution of an individual. Such 
personalised drugs will expectedly be of the desired 
efficacy and will overcome the problem of adverse 
reactions some of which are potentially fatal (Human 
Genome Project Information, 2000c; Sadee, 2002).  
Gene therapy - the use of genes for the treatment of 
diseases - is another type of therapy that would receive a 
boost from the completion of the human genome Project. 
Gene therapy, which involves the use of normal genes to 
supplement or replace a defective gene, or to suppress 
the expression of an undesirable gene, e.g., tumour 
genes, is already a rapidly evolving field in therapeutic 
medicine and holds great hopes for the treating and 
curing of both genetic and acquired diseases (Noguchi, 
2003;   Prchal,   2003) In   addition   to   the    spectacular  
 




success recorded in the treatment of severe combined 
immunodeficiency (Engel et al., 2003; Hacein-Bey-Abina 
et al 2003), significant progress has been made in the 
development of gene therapy protocols for a number of 
diseases including cystic fibrosis, HIV infection, type 1 
diabetes, a number of haemoglobin disorders, a variety of 
cancers and cardiovascular diseases (Nettelbeck et al., 
2000; Romano et al., 2000., Russell and Peng, 2003., 
Griesenbach et al., 2003; Moon et al., 2003., Persons, 
2003; Zhang and Lui, 2003). It is thought that the 
efficiency of gene therapy will improve in the near future 
and the procedure may become routine in the treatment 
of single gene disorders in less than 2 decades from now 
(Dzau, 2003; Prchal, 2003). 
 
 
ETHICAL, LEGAL AND SOCIAL ISSUES 
 
Expectedly, the different potential applications of 
genomics already discussed raise a number of ethical, 
social and legal issues, which must be addressed before 
the full potential impact of the human genome project on 
medicine can be realised. In anticipation of these 
problems, between 3 and 5% of the annual human 
genome project budget of the U.S. Department of Energy 
(DOE) and the National Institutes of Health (NIH) was 
devoted to studying the ethical, legal, and social issues 
(ELSI) that may arise from the availability of genetic 
information as a result of the genome project (HGPI, 
2003b). The greatest concern seems to be expressed 
about genetic testing because of the need to distinguish 
the ‘significance’ of such tests in the diagnosis of the 
highly penetrant genetic disorders, where the 
identification of a mutation serves as a very reliable 
predictor of disease, and the diagnosis of the 
multifactorial diseases, where the detection of a mutation 
can only predict an increased or reduced susceptibility to 
a particular disorder (Bove et al., 1997; Foster and Sharp, 
2000). There are also strong concerns that the availability 
of information on the entire genetic make up of 
individuals, including their predisposition to potentially 
fatal illnesses, for which there are still no cures, based on 
which predictions of a potentially shortened life 
expectation can be made, would lead to discriminations 
in the hands of employees and insurance companies 





Despite the progress already recorded in the different 
areas of medicine and the potentials discussed, it will still 
take a while and a lot of research before the full medical 
benefits of the human genome project will be realised, 
particularly in the field of pharmacogenomics and gene 
therapy, where progress has been rather slow (Dunham, 
2000; Romano et al., 2000). It is estimated that many of 
the new DNA-based diagnostic tests will become 





disorders will become routine clinical practices by 2020 
(Drell and Adamson, 2003).  
There are also genuine fears that the cost of clinical 
care in the post genomic era would rise above what the 
average person can afford. If this is not addressed, only 
the rich can afford the new therapies. At an estimated 
cost of $1000 USD for the sequencing of the complete 
genome of an individual and the likely claim of patent 
rights for some of the gene tests, this is likely to be the 
case. The implication of this is that the already worrying 
gap between standard of health care in the developed 
and developing countries will widen even further in the 
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